Komsing MethavigulArjbordin WinijkulSirin ApiyasawatRatikorn MethavigulThanasak PatmukPattraporn SrirattanaPraprut ThanakitcharuKulyot JongpiputvanichSumon TangsuntornwiwatAhthit YindeengamRungroj KrittayaphongTomorn ThongsriKriengkrai HengrussameeWattana WongtheptienPornchai NgamjanyapornArintaya PhrommintikulSmonporn BoonyaratavejPongpun JitthamTreechada WisaratapongRungroj KrittayaphongRoj RojjarekampaiSomchai DutsadeevettakulChaiyasith WongvipapornThanita BoonyapiphatWeerapan WiwatworapanKhanchai SiriwattanaThoranis ChantraratKasem RatanasumawongWiwat KanjanarutjawiwatSuchart ArunsiriwattanaUdon Thani Center HospitalNakornping HospitalLampang HospitalChonburi Regional HospitalPrapokklao HospitalChulalongkorn UniversityPolice General HospitalNaresuan UniversityVajira HospitalKhon Kaen UniversityFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityMahidol UniversityThammasat UniversityBuddhachinaraj HospitalFaculty of Medicine, Siriraj Hospital, Mahidol UniversityPhramongkutklao College of MedicinePrince of Songkla UniversityChiang Mai UniversityRatchaburi Regional HospitalGolden Jubilee Medical CenterCharoenkrungpracharak HospitalSapphasitthiprasong HospitalSurat Thani HospitalCentral Chest Institute of ThailandMaharat Nakorn Ratchasima HospitalChiangrai Prachanukroh Hospital2020-11-182020-11-182020-10-01Journal of the Medical Association of Thailand. Vol.103, No.10 (2020), 987-995012522082-s2.0-85092789394https://repository.li.mahidol.ac.th/handle/123456789/60077© JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND | 2020. Background: A substantial number of patients with non-valvular atrial fibrillation (NVAF) and a CHA2DS2-VASc score of 0 (i.e., low-risk group) use oral anticoagulants (OACs). Objective: To investigate the rate and reasons for OAC use in Thai patients with NVAF and having a CHA2DS2-VASc score of 0. Materials and Methods: A nationwide observational multicenter registry of patients with NVAF was set up in Thailand. The patients’ demographic and clinical data were recorded on a case record form and then entered into a web-based data collection and management system. Results: One hundred seventy-six patients with NVAF and a CHA2DS2-VASc score of 0 were included. The average age was 53.9±8.2 years old, and all patients were male. Forty-six (26.1%) of the patients received OACs. NVAF patients receiving OACs had a longer duration of AF, more persistent and permanent AF, and mild left ventricular dysfunction. NVAF patients not receiving OACs were significantly more likely to be taking antiplatelet drugs. The reasons for using OACs in patients with a CHA2DS2-VASc score of 0 included thrombus in the left atrial appendage, post-AF ablation, planned cardioversion, hypertrophic cardiomyopathy, hyperthyroidism, and endomyocardial fibrosis. Physicians or patients preferred OAC use despite having a CHA2DS2-VASc score of 0 in 24 patients (52.2%). The use of OACs did not decrease clinical events, but it increased the bleeding risk. Conclusion: Among Thai NVAF patients with CHA2DS2-VASc score of 0, OAC was used in 26.1%. Some stroke risk factors were identified but were not included in the current risk scoring tool.Mahidol UniversityMedicineArticleSCOPUS10.35755/jmedassocthai.2020.10.11529